Next to these compounds, other novel FAP tracers have also shown promising imaging results in preclinical and clinical case studies [4, 9], and currently, multiple clinical trials for FAP-targeted theranostics are ongoing in various cancer types (e.g., NCT04849247, NCT05262855, NCT04939610, NCT04621435). The gene discussed is FAP; the disease is cancer.